Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reisa Sperling

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 31, 2009
Early risk assessment for Alzheimer's diseaseMaria C Carrillo, Andrew Blackwell, Harald Hampel, et al.
Medrxiv : the Preprint Server for Health Sciences|September 26, 2025
Continuum of Core 1 Biomarkers in Preclinical Alzheimer's DiseaseLeonardino A Digma, Christina B Young, Joseph R Winer, et al.
NPJ Dementia|July 6, 2026
Common and rare variant analyses implicate <i>JARID2</i> in cerebral tau depositionTamil Iniyan Gunasekaran, Devendra Meena, Annie J Lee, et al.
Alzheimer Disease and Associated Disorders|May 24, 2016
The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's DiseaseSarah D Tarrant, Shoshana H Bardach, Kendra Bates, et al.
Neuroimage|November 22, 2011
The ADNI Publication Policy: commensurate recognition of critical contributors who are not authorsOrest Hurko, Sandra E Black, Rachelle Doody, et al.
Alzheimer'S Research & Therapy|August 11, 2017
On the path to 2025: understanding the Alzheimer's disease continuumPaul S Aisen, Jeffrey Cummings, Clifford R Jack, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2025
Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trialJoshua D Grill, Rema Raman, Charlene Flournoy, et al.
Annals of Neurology|October 13, 2023
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer DiseaseJoshua D Grill, Charlene Flournoy, Shobha Dhadda, et al.
Neurology|February 13, 2018
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumabEnchi Liu, Dai Wang, Reisa Sperling, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 29, 2016
Challenges, solutions, and recommendations for Alzheimer's disease combination therapyJames A Hendrix, Randall J Bateman, H Robert Brashear, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 31, 2009
Early risk assessment for Alzheimer's diseaseMaria C Carrillo, Andrew Blackwell, Harald Hampel, et al.
Medrxiv : the Preprint Server for Health Sciences|September 26, 2025
Continuum of Core 1 Biomarkers in Preclinical Alzheimer's DiseaseLeonardino A Digma, Christina B Young, Joseph R Winer, et al.
NPJ Dementia|July 6, 2026
Common and rare variant analyses implicate <i>JARID2</i> in cerebral tau depositionTamil Iniyan Gunasekaran, Devendra Meena, Annie J Lee, et al.
Alzheimer Disease and Associated Disorders|May 24, 2016
The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's DiseaseSarah D Tarrant, Shoshana H Bardach, Kendra Bates, et al.
Neuroimage|November 22, 2011
The ADNI Publication Policy: commensurate recognition of critical contributors who are not authorsOrest Hurko, Sandra E Black, Rachelle Doody, et al.
Alzheimer'S Research & Therapy|August 11, 2017
On the path to 2025: understanding the Alzheimer's disease continuumPaul S Aisen, Jeffrey Cummings, Clifford R Jack, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2025
Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trialJoshua D Grill, Rema Raman, Charlene Flournoy, et al.
Annals of Neurology|October 13, 2023
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer DiseaseJoshua D Grill, Charlene Flournoy, Shobha Dhadda, et al.
Neurology|February 13, 2018
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumabEnchi Liu, Dai Wang, Reisa Sperling, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 29, 2016
Challenges, solutions, and recommendations for Alzheimer's disease combination therapyJames A Hendrix, Randall J Bateman, H Robert Brashear, et al.
Pageof 10